Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) and VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership.
Earnings and Valuation
This table compares Avalo Therapeutics and VYNE Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Avalo Therapeutics | $440,000.00 | 597.79 | -$35.13 million | ($5.36) | -2.65 |
| VYNE Therapeutics | $500,000.00 | 39.60 | -$39.83 million | ($0.78) | -0.76 |
Analyst Ratings
This is a summary of recent ratings for Avalo Therapeutics and VYNE Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Avalo Therapeutics | 1 | 0 | 9 | 1 | 2.91 |
| VYNE Therapeutics | 1 | 3 | 0 | 0 | 1.75 |
Avalo Therapeutics currently has a consensus price target of $34.88, suggesting a potential upside of 145.43%. VYNE Therapeutics has a consensus price target of $4.50, suggesting a potential upside of 656.56%. Given VYNE Therapeutics’ higher possible upside, analysts clearly believe VYNE Therapeutics is more favorable than Avalo Therapeutics.
Volatility and Risk
Avalo Therapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 2.02, meaning that its stock price is 102% more volatile than the S&P 500.
Profitability
This table compares Avalo Therapeutics and VYNE Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Avalo Therapeutics | N/A | -88.43% | -73.86% |
| VYNE Therapeutics | -6,425.19% | -80.84% | -66.20% |
Insider and Institutional Ownership
87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 3.0% of Avalo Therapeutics shares are owned by company insiders. Comparatively, 3.0% of VYNE Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
About Avalo Therapeutics
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
About VYNE Therapeutics
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
